Observe Medical further expands and strengthens the global patent protection for Sippi® proprietary technology
Oslo May 6, 2021 – Observe Medical ASA (OSE: OBSRV), announces that Sippi® automated and digital urine meter recently received new patent approvals in India, China and Brazil, further expanding and strengthening the global patent protection for Sippi® proprietary technology.
“We are pleased to announce that Sippi® since end March this year, has received three important patent approvals - in India, China and Brazil respectively, for SippCoat® and SippSense® proprietary technologies, thus further strengthening the patent protection and supporting the current commercial rollout in Europe as well as the planned expansion into North America and Asia,” says Björn Larsson, CEO Observe Medical.
Observe Medical's product Sippi® is the only automated digital urine meter with possibility for wireless data transfer (SippLink™) to the hospital patient data management systems and detects (SippSense®) and hinders (Sippcoat®) biofilm formation, that can lead to urinary infections. Sippi® patent protection comprise five patent families and over 60 individual approved patients in Europe, US / North America and in Asia.
Observe Medical current focus is the clinical rollout of Sippi® in the Nordic region and selected countries in rest of Europe to get systems in clinical use, and to receive customer feedback.
“COVID-19 pandemic is highlighting the need for increased efficiency in intensive care units and other departments in hospitals, as well as the need for accurate patient data, and to prevent and manage hospital acquired infections. Sippi® is an innovative solution addressing these major challenges, enabled by the proprietary SippSense®, SippCoat® and SippLink® technologies.
“The most recent patent approvals in India, China and Brazil are further strengthening the patent protection of the Sippi® system, including the possibility to apply the SippCoat® technology in other applications, further expanding the commercial opportunity”, Larsson concludes.
For further information, please contact:
Björn Larsson, CEO, mobile: +46 76 620 17 25, E-mail: bjorn.larsson@observemedical.com
About Observe Medical https://observemedical.com/
Observe Medical develops and markets and sells innovative hospital products that contribute to increased patient safety and a more efficient care system. The company’s ambition is to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in combination with targeted M&A. The company’s headquarter is in Oslo, Norway and its operations is based out of Gothenburg, Sweden. Observe Medical has a direct sales organization in the Nordics and a distributor network internationally. Observe Medical's product Sippi® is the only automated digital urine meter with possibility for wireless data transfer to the hospital patient data management systems and hinders biofilm formation that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched with focus on selected markets and hospitals in Nordics and in Europe.